The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
New therapeutic approaches for metastatic thyroid carcinoma
Abstract
Treatment of metastatic differentiated thyroid cancer (DTC) includes the use of radioiodine and suppressive thyroid hormone treatment. A third of patients with distant metastases (who have radioiodine uptake, are younger than 40 years, have small metastases, and have well differentiated thyroid tumour) can be cured with radioiodine treatment. For other patients, there are no effective treatment modalities. However, the recent availability of molecularly targeted treatments has led to changes in the treatment strategy for DTC in patients with distant metastases, especially in those who are resistant to radioiodine treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DePTC, which accounts for approximately 5-10% of patients with PTC, leads to resistance to traditional therapeutic strategies and worsens prognosis [9, 10, 29].”
From Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells (2017) · cites this paper as [29]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Williams Textbook of Endocrinology
Melmed, S., & Polonsky, K. S. (2016) · Elsevier eBooks · doi:10.1016/c2013-0-15980-6 · Cited by 3,715
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,379
International Histological Classification of Tumours
Weller, R. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.6.692-d · Cited by 2,047
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,014
Pacini, F., Schlumberger, M. J., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W. M., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,970
Self-citationDurante, C., Haddy, N., Baudin, É., Leboulleux, S., Hartl, D. M., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J., de Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,670
Self-citationTyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,402
HAY, I. D., Thompson, G. B., Grant, C. S., Bergstralh, E. J., Dvorak, C. E., Gorman, C. A., Maurer, M. S., McIver, B., Mullan, B. P., Oberg, A. L., et al. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6612-1 · Cited by 731
Nikiforova, M. N., Lynch, R. A., Biddinger, P. W., Alexander, E. K., Dorn, G. W., Tallini, G., Kroll, T. G., & Nikiforov, Y. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021907 · Cited by 711
Research works printed but not linked: 1
- Brierley, 2006, Bortezomib in patients with metastatic differentiated thyroid cancer: preliminary results of a multicenter phase II study. American Thyroid Association meeting, Phoenix, October 2006, Thyroid, 16, 857
Cited by
Sorted by citations
Items 101–143 of 143
(2007) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.1339 · Cited by 6
Mross, K. B. (2008) · Pharmazie in unserer Zeit · doi:10.1002/pauz.200800281 · Cited by 5
Thyroid Cancer Brain Metastases and Thyroglobulin
Díaz, B. C., Ramos, D. C., Spínola-Maroño, H., Soto, G. R., Olvera-Manzanilla, E., Monroy-Sosa, A., Lorenzana-Mendoza, N. A., García, M. G., & Herrera‐Gómez, Á. (2016) · Journal of Endocrinology and Metabolism · doi:10.14740/jem351w · Cited by 5
Radioiodine Therapy of Differentiated Thyroid Cancer
Seregni, E. C., Mallia, A., Chiesa, C., Scaramellini, G., Massimino, M., & Bombardieri, E. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4021-5_8 · Cited by 5
“However, relatively low response rates have been achieved to date; the most likely reason being that there are other defects, other than impaired NIS expression, that explain poor radioiodine uptake by dedifferentiated cells [ 58 ] .”
BackgroundA Case Report of "Spinal Cord Apoplexy" Elicited by Metastatic Intramedullary Thyroid Carcinoma
Choi, I. J., Chang, J. C., Kim, D. W., & Choi, G. (2012) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2012.51.4.230 · Cited by 5
Tripathy, S. R., Deo, R. C., Mishra, S., Dhir, M. K., Nath, P. C., & Satapathy, M. C. (2016) · Surgical Neurology International · doi:10.4103/2152-7806.182544 · Cited by 5
“[11] The occurrence of metastatic lesions with hemorrhage arising from a PTC is extremely rare.[5] A few cases of lower gastrointestinal metastatic hemorrhage have been reported, which were associated with familial adenomatous polyposis.”
BackgroundRAN-S100A10-EGFR axis facilitates papillary thyroid cancer metastasis by PI3K/AKT signaling
Song, W., Liu, Z., Shi, C., Wang, G., He, L., Chen, Z., Li, Y., Yu, Y., Jiang, R., Wang, X., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08649-6 · Cited by 4
“Among all malignant thyroid neoplasms, papillary thyroid carcinoma (PTC) is the most prevalent well-differentiated carcinoma, constituting approximately 80 – 85% of all thyroid cancers [2, 3].”
Sirakriengkrai, K., Tepmongkol, S., Keelawat, S., & Techavijit, U. (2020) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001340 · Cited by 4
Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers
Roy, M., Edet‐Sanson, A., Lefèbvre, H., Véra, P., & Decazes, P. (2022) · Diagnostics · doi:10.3390/diagnostics12102381 · Cited by 4
“The most common site of metastasis of DTC is the lungs [3,7,10,24,40], a finding which was also true in our study with 71% of patients bearing lung metastasis.”
BackgroundResultIdentification of Thyroid Stimulating Hormone Receptor Inverse Agonists
Huang, W., Englund, E. E., Titus, S., Southall, N. T., Zheng, W., Ferrer, M., Marugán, J., Neumann, S., & Gershengorn, M. C. (2013) · Cited by 4
Surgical management of follicular carcinoma of thyroid with spinal metastasis
Chander, A., Jayabalan, V., Ram, G. G., Shanmugasundaram, G., & Kannan, K. K. (2015) · International Surgery Journal · doi:10.18203/2349-2902.isj20151086 · Cited by 4
Evaluation of CYFRA 21.1 as a dedifferentiation marker of advanced thyroid cancer
Bal, C., Malapure, S. S., Patel, C., & Lakshmy, R. (2020) · Indian Journal of Nuclear Medicine · doi:10.4103/ijnm.ijnm_148_19 · Cited by 4
“Well‐differentiated thyroid carcinomas have good prognosis, but as dedifferentiation sets in, the survival rates go down.[1,2] Response in such cases to conventional treatment modalities such as radiotherapy and chemotherapy is poor,[3,4] and therefore, there is a need for new effective treatment modalities.”
BackgroundDUO, L. J., Jiang, R., Wang, B., HUA, M. C., WEI, S. L., & Lv, Y. (2015) · Oncology Letters · doi:10.3892/ol.2015.3174 · Cited by 3
Angiogenèse et cancer de la thyroïde
Francis, Z., Baudin, É., Leboulleux, S., & Schlumberger, M. J. (2009) · La Presse Médicale · doi:10.1016/j.lpm.2008.10.026 · Cited by 3
Self-citationConcurrent Thyroid Papillary Carcinoma and Medullary Carcinoma in The Thyroid
Olgen, U., Dilek, G. B., & Özaslan, C. (2016) · Acta Oncologica Turcica · doi:10.5505/aot.2016.94695 · Cited by 2
Krüger, M., Bauer, J. W., & Grimm, D. G. (2017) · SpringerBriefs in space life sciences · doi:10.1007/978-3-319-64054-9_7 · Cited by 2
Pacini, F., Chiofalo, F., & DeGroot, L. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00092-5 · Cited by 2
AN ALTERNATIVE THERAPY OPTION IN METASTATIC THYROID CANCER: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY
Çınkır, H. Y., & Elboğa, U. (2020) · Journal of Istanbul Faculty of Medicine / İstanbul Tıp Fakültesi Dergisi · doi:10.26650/iuitfd.2019.0097 · Cited by 2
“The OS rate of patients with non-RAI-avid is notably lower than that of patients with iodine-avid lesions (13-15).”
Background(2007) · Annales d Endocrinologie · doi:10.1016/s0003-4266(07)78636-5 · Cited by 2
Therapy for bone metastasis from different cancers ⁎
Zhang, Z., Tan, P., Mi, B., Song, C., Deng, Y., & Guan, H. (2016) · Oncology and Translational Medicine · doi:10.1007/s10330-016-0141-0 · Cited by 1
Differentiated thyroid cancer and positron emission computed tomography: when, how and why?
Pelaz, A. C., Rodrigo, J. P., Zafereo, M., Nixon, I. J., Guntinas‐Lichius, O., Randolph, G. W., Civantos, F., Pace‐Asciak, P., Jara, M. A., Kuker, R. A., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2529285 · Cited by 1
“In this context, FDG PET/CT offers a more standardized method for patient selection compared to traditional criteria, such as tumor size progression based on RECIST (Response Evaluation Criteria in Solid Tumors) guidelines [42,43].”
Guo, H., Qi, Y., Zhang, J., Wu, J., & Sun, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-37103-y · Cited by 1
“DTC) 4,5 .”
Dumont, R. A., Mueller‐Brand, J., & Walter, M. A. (2012) · Medical radiology · doi:10.1007/174_2012_672 · Cited by 1
Medical Management of Persistent or Recurrent Differentiated Thyroid Carcinoma
Jun, J. Y., & Manni, A. (2008) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2008.05.005 · Cited by 1
“Eighty percent of papillary thyroid carcinomas were associated with mutations in genes involving the RAS-RAF-MEKMAPK cascade [63].”
BackgroundOnoda, N., Kawajiri, H., Kashiwagi, S., Nakamura, M., Takashima, T., Osawa, M., Wakasa, K., Ishikawa, T., & Hirakawa, K. (2012) · International Cancer Conference Journal · doi:10.1007/s13691-012-0070-x · Cited by 1
“Approximately 5 % of these patients demonstrated de-differentiation profiles in the recurrent focus [1] and displayed poor outcomes after showing resistance to conventional therapeutic strategies [3].”
BackgroundFollow-up of Thyroid Cancer Patients and Treatment of Distant Metastases
Schlumberger, M. J., Brassard, M., & Leboulleux, S. (2012) · Medical radiology · doi:10.1007/174_2012_746 · Cited by 1
“None have used response criteria in solid tumors (RECIST), and many trials included heterogeneous cohorts of DTC, anaplastic, and medullary thyroid cancer patients grouped together (Baudin and Schlumberger 2007; Schlumberger and Sherman 2009).”
BackgroundSelf-citationA Boolean network model for invasive thyroid carcinoma
Espinal-Enriquez, J., Meja-Pedroza, R. A., & Lemus, E. H. (2016) · Conference on Artificial Life (ALIFE) · doi:10.1162/978-0-262-33936-0-ch091 · Cited by 1
Radiolabeled Somatostatin Analogues in the Treatment of Non-GEP-NET Tumors
Versari, A., Filice, A., Casali, M., Sollini, M., & Frasoldati, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-63067-0_37 · Cited by 1
Radioiodine Therapy in Differentiated Thyroid Cancer
Isah, A. R., Abubakar, S., Yunusa, G. H., Jawa, Z. M., & Momodu, J. I. (2023) · Journal of the Nigerian Academy of Medicine · doi:10.4103/jnam.jnam_40_22 · Cited by 1
Evaluation of the Malignancy Risk in Nodules Expanding the Thyroid Gland Capsule
Arslan, İ., Bostan, H., Hepşen, S., Akhanlı, P., Sencar, M. E., & Çakal, E. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2356-8223 · Cited by 1
“Thy - roid nodules are mostly benign; however, aggressive thyroid can - cer cases with recurrences and distant metastases are seen at a sub - stantial level [5–8].”
Liver Metastases in Thyroid Cancer
Kruijff, S., van der Horst‐Schrivers, A. N. A., & de Jong, K. P. (2014) · Springer eBooks · doi:10.1007/978-3-319-09293-5_13 · Cited by 1
“Noteworthy, metastasized thyroid cancer survival rates are variable with reported 10-year survival rates up to 92 % [ 28 ].”
BackgroundJambi, L. (2022) · Medical Science · doi:10.54905/disssi/v26i129/ms473e2571 · Cited by 1
“Surg Clin North Am 2000; 80(2):571-580.”
Tobias, J. S., & Hochhauser, D. (2009) · Wiley eBooks · doi:10.1002/9781444306361.ch20 · Cited by 1
Aslan, A., Mert, T., Uçaner, B., Hançerlioğulları, O., Karaman, Ç., Çiftçi, M. S., Acar, S., Göktaş, S. S., Anadolulu, Z., Özkara, M., et al. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2641 · Cited by 1
Traitements médicaux des tumeurs endocrines rares
Francis, Z., & Schlumberger, M. J. (2010) · Springer eBooks · doi:10.1007/978-2-287-72070-3_78
Self-citationMetastatic Thyroid Cancer: Evaluation and Treatment
Tuttle, R. M. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976117.037
BRAF V600E mutation in papillary thyroid carcinoma: a potential target for therapy?
Soares, P., Preto, A., & Sobrinho-Simões, M. A. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.29
Tobias, J. S., & Hochhauser, D. (2014) · Wiley eBooks · doi:10.1002/9781118468753.ch20
Cote, G. J. (2010) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.4812956.4725054
Daskalakis, M., Henne, K., Henß, H., Martens, U. M., Digel, W., Engelhardt, R., Otto, F., Deschler-Baier, B., Berger, D. P., Allgaier, H., et al. (2008) · Springer eBooks · doi:10.1007/978-3-540-73277-8_8
Sandu, N., & Schaller, B. J. (2014) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.131663
Papillary, follicular, and anaplastic thyroid carcinoma and lymphoma
Leboulleux, S., & Schlumberger, M. J. (2011) · doi:10.1093/med/9780199235292.003.3346
Self-citationJambi, L. (2022) · Journal on oncology · doi:10.52768/2692-563x/1067
Metadata
- Authors
- Baudin, E., & Schlumberger, M.
- Affiliations
- Institut Gustave Roussy (FR)
- ORCID
- Schlumberger, Martin
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2007-02
- Volume
- 8
- Issue
- 2
- Pages
- 148-156
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2132185197
- Cited by
- 143
- References
- 77
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 6 · 2020: 6 · 2019: 1 · 2018: 9 · 2017: 4 · 2016: 11 · 2015: 13 · 2014: 11 · 2013: 7 · 2012: 8
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- metastatic thyroid cancer, differentiated thyroid cancer, radioiodine therapy, targeted therapy, radioiodine resistance, distant metastasis, treatment options
- MeSH terms
- Humans, Iodine Radioisotopes, Thyroid Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
